The Effects of Desferroxamine on Bone and Bone Graft Healing in Critical-Size Bone Defects

Annals of Plastic Surgery
Serbulent GuzeyAtilla Ertan

Abstract

Autogenous bone grafts are still the criterion standard treatment option in critical-size bone defect reconstructions, and many therapies can affect its incorporation. In this study, it was aimed to research the effects of desferroxamine (DFO) application on bone and bone graft healing due to the effects of osteoblast and osteoclast regulation and stimulation of angiogenesis. Rat zygomatic arch critical-size bone defect model (5 mm) was used as the experimental model. Thirty-two Sprague-Dawley rats (64 zygomatic arches) were divided into 4 groups (16 zygomatic arches in each). In groups 1 and 2, defects were reconstructed with the bone grafts harvested from the other side, and the right arc was named as group 1, and the left was group 2. At group 1, 200 μM/300 μL dosage of DFO was injected at the zygomatic arch region starting at the seventh day preoperatively and lasting until the 45th day postoperatively. Group 2 animals were defined as the control group of group 1, and 0.9% NaCl injection was applied. In groups 3 and 4, there was no repair after the formation of defects, and the right arc region was treated with DFO, and left was treated with 0.9% NaCl for postoperative 45 days, respectively. Radiological (computed tomograph...Continue Reading

References

Mar 1, 1988·Plastic and Reconstructive Surgery·G S LaTrentaC Orentreich
Jan 1, 1987·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·M J MoralesC F Gottlieb
May 1, 1983·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·R E Marx
Jul 1, 1982·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·J W FrameC L Brady
Jul 1, 1993·Bone·C H Turner, D B Burr
Sep 1, 1996·Molecular and Cellular Biology·J A ForsytheG L Semenza
Feb 1, 1997·Endocrine Reviews·N Ferrara, T Davis-Smyth
Jan 1, 1997·Archives of Orthopaedic and Trauma Surgery·P VirolainenH T Aro
Feb 7, 2001·American Journal of Physiology. Cell Physiology·D S SteinbrechM T Longaker
Jul 27, 2000·The Cleft Palate-craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association·K M Chow, A B Rabie
Jul 12, 2005·Biochemical and Biophysical Research Communications·Jörg FiedlerRolf E Brenner
Dec 20, 2005·Expert Review of Medical Devices·Cato LaurencinSaadiq F El-Amin
Apr 28, 2007·International Journal of Surgery·Bassem EmadA Bakr M Rabie
Jan 28, 2009·Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS·Myung Good KimSang Woo Lee
Jun 17, 2009·Journal of Orthopaedic Surgery and Research·John Street, Brian Lenehan
Jan 5, 2011·Plastic and Reconstructive Surgery·Asako YamaguchiYasushi Sugawara
Mar 30, 2012·Plastic and Reconstructive Surgery·Alexis DonneysSteven R Buchman
Apr 25, 2012·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Weibin ZhangShijing Qiu
May 1, 2013·Plastic and Reconstructive Surgery·Alexis DonneysSteven R Buchman

❮ Previous
Next ❯

Citations

Jul 9, 2020·Tissue Engineering. Part B, Reviews·Maximilian M MengerTina Histing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.